<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Inmune Bio Inc — News on 6ix</title>
<link>https://6ix.com/company/inmune-bio-inc</link>
<description>Latest news and press releases for Inmune Bio Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/inmune-bio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683583ee78dffbe2df0fce58.webp</url>
<title>Inmune Bio Inc</title>
<link>https://6ix.com/company/inmune-bio-inc</link>
</image>
<item>
<title>INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-announces-new-preclinical-data-at-aacr-2026-demonstrating-inb03-xpro1595-overcomes-resistance-and-reduces-metastases-in-her2-positive-breast-cancer-models</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-announces-new-preclinical-data-at-aacr-2026-demonstrating-inb03-xpro1595-overcomes-resistance-and-reduces-metastases-in-her2-positive-breast-cancer-models</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company focused on</description>
</item>
<item>
<title>INmune Bio Inc. Announces 2025 Results and Provides Business Update</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-announces-2025-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-announces-2025-results-and-provides-business-update</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Company to Host Conference Call Today, March 30, at 4:30pm ET BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the</description>
</item>
<item>
<title>INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ:</description>
</item>
<item>
<title>INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bios-mindful-trial-featured-at-adpd-2026-plenary-as-successful-example-of-how-to-approach-clinical-trials-targeting-inflammation-in-early-alzheimers-disease</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bios-mindful-trial-featured-at-adpd-2026-plenary-as-successful-example-of-how-to-approach-clinical-trials-targeting-inflammation-in-early-alzheimers-disease</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug</description>
</item>
<item>
<title>INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-to-detail-xpro1595-registrational-strategy-in-upcoming-alzheimers-webinar</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-to-detail-xpro1595-registrational-strategy-in-upcoming-alzheimers-webinar</guid>
<pubDate>Mon, 23 Feb 2026 14:25:00 GMT</pubDate>
<description>Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595Boca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar focused on the registrational pathway of XPro1595 (“XPro™”) for the treatment of early Alzheimer’s disease on February 27, 2026 at 9:30 a.m. ET. Post the completion of</description>
</item>
<item>
<title>INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-announces-upcoming-webinar-to-present-new-clinical-data-on-cordstromtm-for-rdeb</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-announces-upcoming-webinar-to-present-new-clinical-data-on-cordstromtm-for-rdeb</guid>
<pubDate>Thu, 19 Feb 2026 17:15:00 GMT</pubDate>
<description>Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study Boca Raton, FL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar on CORDStrom for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) on February 26, 2026 at 1:00 p.m. ET. The session</description>
</item>
<item>
<title>INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-announces-fda-alignment-120000419</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-announces-fda-alignment-120000419</guid>
<pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
<description>Agency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for Registrational Development Boca Raton, FL, Feb. 12, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune Bio” or the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it received the official minutes from its End-of-Phase 2 (Type B) meeting with the U.S. Food and Drug Administration (FDA). The minutes confirm re</description>
</item>
<item>
<title>INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-advances-cordstrom-towards-130000305</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-advances-cordstrom-towards-130000305</guid>
<pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
<description>Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval process and reduce time to market Boca Raton, FL, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, today announced a critical step toward the commercialization of CORDStrom™ for the treatment of recessi</description>
</item>
<item>
<title>INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-issues-shareholder-142500156</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-issues-shareholder-142500156</guid>
<pubDate>Tue, 27 Jan 2026 14:25:00 GMT</pubDate>
<description>Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow Shareholders, As we reflect on 2025, I want to thank you for your continued support of INmune Bio. This past year marked an important period of execution, discipline, and focus as we advanced our mission to develop innovative therapies that address serious neuroinflammatory and immunol</description>
</item>
<item>
<title>Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform</title>
<link>https://6ix.com/company/inmune-bio-inc/news/peer-reviewed-study-highlights-therapeutic-120000571</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/peer-reviewed-study-highlights-therapeutic-120000571</guid>
<pubDate>Fri, 05 Dec 2025 12:00:00 GMT</pubDate>
<description>Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, such as INmune’s CORDStrom™ platform. The article, titled, “Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions,” was published in the peer-reviewed journal Cytotherapy</description>
</item>
<item>
<title>INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-reports-phase-2-130000946</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-reports-phase-2-130000946</guid>
<pubDate>Mon, 01 Dec 2025 13:00:00 GMT</pubDate>
<description>Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer’s disease (AD) and elevated neuroinflammation. The results will be presented at the 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), being held on December 1-4, 2025 in S</description>
</item>
<item>
<title>INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-announces-two-presentations-130000850</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-announces-two-presentations-130000850</guid>
<pubDate>Tue, 18 Nov 2025 13:00:00 GMT</pubDate>
<description>Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), in San Diego, CA on December 1-4, 2025. Presentations: Title:XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial Date:Monday, December 1, until Tuesday December 2</description>
</item>
<item>
<title>INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-announces-third-200500183</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-announces-third-200500183</guid>
<pubDate>Thu, 30 Oct 2025 20:05:00 GMT</pubDate>
<description>Company to Host Conference Call Today, October 30, at 4:30pm ETBOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2025 and provides a business update. Q3 2025 and Recent Corporate Highlights CORDStrom™ Platform: Announced suc</description>
</item>
<item>
<title>INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-report-third-110000791</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-report-third-110000791</guid>
<pubDate>Thu, 23 Oct 2025 11:00:00 GMT</pubDate>
<description>Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 23, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), INmune Bio Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that it will host a conference call on Thursday, October 30, 2025 at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2025 and to provide a corporate update. Conference Call Information To</description>
</item>
<item>
<title>INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-participate-dermatologic-rare-110000557</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-participate-dermatologic-rare-110000557</guid>
<pubDate>Tue, 14 Oct 2025 11:00:00 GMT</pubDate>
<description>Boca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025 at the Hard Rock Hotel in New York City. The panel will be moderated by Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Re</description>
</item>
<item>
<title>INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-announces-submission-phase-120000390</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-announces-submission-phase-120000390</guid>
<pubDate>Mon, 29 Sep 2025 12:00:00 GMT</pubDate>
<description>Boca Raton, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manuscript detailing the results of its Phase 2 MINDFuL trial. The manuscript, titled, “XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial,” has been submitted for peer review to npj Dementia, a Nature Portfolio journal. The detailed man</description>
</item>
<item>
<title>INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-announces-successful-completion-120000248</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-announces-successful-completion-120000248</guid>
<pubDate>Mon, 15 Sep 2025 12:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or “the Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced the successful completion of its first full-scale pilot commercial manufacturing run of CORDStrom™, an off-the-shelf, allogeneic, umbilical cord tissue-derived mesenchymal stromal cell therapy for the treatment of Reces</description>
</item>
<item>
<title>INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-announces-second-200500121</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-announces-second-200500121</guid>
<pubDate>Thu, 07 Aug 2025 20:05:00 GMT</pubDate>
<description>Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended June 30, 2025 and provides a business update. Q2 2025 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): Released top-line da</description>
</item>
<item>
<title>INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-care-pc-trial-120000411</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-care-pc-trial-120000411</guid>
<pubDate>Mon, 04 Aug 2025 12:00:00 GMT</pubDate>
<description>BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the “CaRe PC” trial) of INKmune™ for men with metastatic castration-resistant prostate cancer (mCRPC) has met its primary and secondary endpoints and is now closed to further enrollment. INKmune™ was well tolerated at all three dose levels in the trial, demonstrating an excellent safety profile, the</description>
</item>
<item>
<title>INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th</title>
<link>https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-report-second-110000309</link>
<guid isPermaLink="true">https://6ix.com/company/inmune-bio-inc/news/inmune-bio-inc-report-second-110000309</guid>
<pubDate>Thu, 31 Jul 2025 11:00:00 GMT</pubDate>
<description>Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, August 7th, 2025 at 4:30pm EDT to discuss results for its quarter ended June 30, 2025 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10</description>
</item>
</channel>
</rss>